GlassScriptPhysician profile
Hasan Bit-Shawish
NPI 1871702779
$8,884.24
in general payments reported to CMS, 2019-2025
53 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $153 · 2021: $121 · 2022: $1,723 · 2023: $1,501 · 2024: $1,967 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,213 · Education: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,213.46 |
| Education | $426.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $794.23 | 2022-2025 | Rybrevant, Erleada, Tecvayli |
| Pfizer INC. | $605.43 | 2022-2025 | |
| Celgene Corporation | $554.74 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $542.54 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $524.01 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $511.32 | 2022-2025 | Piqray, Kisqali |
| Daiichi Sankyo INC. | $373.07 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Gilead Sciences, INC. | $362.63 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $335.48 | 2020-2025 | Opdivo, Krazati, Opdualag |
| Abbvie INC. | $299.28 | 2022-2025 | Venclexta |
| Incyte Corporation | $285.00 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| Eisai INC. | $268.65 | 2022-2025 | |
| Genzyme Corporation | $252.73 | 2022-2025 | |
| Sobi, INC | $210.33 | 2022-2025 | |
| Genentech USA, INC. | $209.84 | 2022-2025 | Tecentriq, Venclexta, Itovebi |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $175.06 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $172.65 | 2022-2025 | Cabometyx |
| Lilly USA, LLC | $169.62 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $126.02 | 2022-2025 | Libtayo |
| Tesaro, INC. | $121.67 | 2019 | |
| Array Biopharma INC | $117.91 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Rigel Pharmaceuticals, INC. | $112.69 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $112.26 | 2022-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Karyopharm Therapeutics INC. | $109.75 | 2024-2025 | Xpovio |
| Stemline Therapeutics INC. | $103.22 | 2023-2025 | Orserdu |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Tersera Therapeutics LLC | $87.78 | 2022 | |
| Kyowa Kirin, INC. | $85.89 | 2022-2025 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $81.11 | 2022-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $76.42 | 2024-2025 | Monoferric |
| Puma Biotechnology, INC. | $74.82 | 2024-2025 | |
| Beigene USA, INC. | $74.21 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $71.70 | 2024-2025 | Xtandi, Vyloy |
| Sumitomo Pharma America, INC. | $68.99 | 2024-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $66.29 | 2023-2025 | Zepzelca |
| Springworks Therapeutics, INC. | $64.91 | 2024-2025 | Ogsiveo |
| Kite Pharma, INC. | $64.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.81 | 2024 | |
| Aveo Pharmaceuticals, INC. | $47.84 | 2022 | |
| Pharmaessentia USA Corporation | $47.34 | 2023-2025 | Besremi |
| Blueprint Medicines Corporation | $44.85 | 2022-2025 | Ayvakit |
| Mylan Institutional INC. | $39.78 | 2022-2023 | Ogivri, Fulphila |
| Foundation Medicine, INC. | $39.42 | 2023 | |
| Seagen INC. | $38.72 | 2022-2023 | Adcetris |
| Novocure INC. | $35.14 | 2023-2025 | Optune, Optune Lua (Novottf-200t) |
| Beone Medicines USA, INC. | $28.35 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.92 | 2022 | |
| Adc Therapeutics America, INC. | $23.55 | 2025 | |
| Epizyme, INC. | $21.11 | 2022 | |
| Taiho Oncology, INC. | $20.73 | 2024 | |
| Dendreon Pharmaceuticals LLC | $20.63 | 2024 | Provenge |
| Tolmar, INC. | $18.34 | 2023 | |
| Servier Pharmaceuticals LLC | $14.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Bit-Shawish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.